Hydrocl: Advanced Diuretic Therapy for Effective Edema Management
Hydrocl
| Product dosage: 12.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.39 | $47.00 (0%) | 🛒 Add to cart |
| 180 | $0.36 | $70.50 $65.00 (8%) | 🛒 Add to cart |
| 270 | $0.33 | $105.75 $89.00 (16%) | 🛒 Add to cart |
| 360 |
$0.30
Best per pill
|
$141.00 $108.00 (23%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.49 | $44.00 (0%) | 🛒 Add to cart |
| 120 | $0.46 | $58.67 $55.00 (6%) | 🛒 Add to cart |
| 180 | $0.42 | $88.00 $75.00 (15%) | 🛒 Add to cart |
| 270 | $0.40 | $132.00 $107.00 (19%) | 🛒 Add to cart |
| 360 |
$0.39
Best per pill
|
$176.00 $139.00 (21%) | 🛒 Add to cart |
Hydrocl is a prescription diuretic medication containing hydrochlorothiazide, designed for the clinical management of fluid retention (edema) and hypertension. It functions by inhibiting sodium reabsorption in the distal convoluted tubule of the nephron, promoting excretion of water and electrolytes. This mechanism provides a controlled reduction in extracellular fluid volume, supporting cardiovascular and renal treatment goals under medical supervision. Hydrocl is indicated for use in adults where diuretic therapy is deemed appropriate based on individual patient assessment.
Features
- Active ingredient: Hydrochlorothiazide 25 mg per tablet
- Pharmacologic class: Thiazide diuretic
- Mechanism: Inhibition of sodium-chloride symporter in distal tubule
- Onset of action: Within 2 hours of administration
- Peak effect: 4–6 hours post-dose
- Duration: 6–12 hours depending on renal function
- Bioavailability: Approximately 50–60%
- Protein binding: 40–60%
- Elimination half-life: 5.6–14.8 hours
- Excretion: Primarily renal (≥95% unchanged)
Benefits
- Reduces peripheral and pulmonary edema through controlled natriuresis
- Lowers blood pressure by decreasing plasma volume and reducing peripheral vascular resistance
- Decreases risk of cardiovascular events associated with fluid overload
- Minimizes hospitalizations for heart failure exacerbations
- Provides predictable pharmacokinetics for dosing consistency
- Compatible with many antihypertensive regimens for combination therapy
Common use
Hydrocl is primarily prescribed for the management of edema associated with congestive heart failure, hepatic cirrhosis, renal dysfunction, and corticosteroid or estrogen therapy. It is also indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. Off-label uses may include treatment of calcium nephrolithiasis, diabetes insipidus, and syndrome of inappropriate antidiuretic hormone secretion (SIADH), though these applications require specialist evaluation.
Dosage and direction
The recommended initial dosage for edema is 25–100 mg once daily or divided doses. For hypertension, initiate with 25 mg once daily, titrating to response. Maximum daily dose should not exceed 100 mg. Administer with or without food, though consistent timing is recommended. Tablets should be swallowed whole with adequate fluid intake. Dosage adjustments are necessary in renal impairment (eGFR <30 mL/min/1.73m² generally requires alternative therapy) and elderly patients. Monitor serum electrolytes within first week of therapy and periodically thereafter.
Precautions
Monitor blood pressure, renal function, and electrolytes regularly. Assess for signs of hypokalemia, hyponatremia, and hypochloremic alkalosis. Use caution in patients with impaired hepatic function or progressive liver disease, as minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Photosensitivity reactions may occur; advise sun protection. Orthostatic hypotension may develop, particularly in volume-depleted patients. Monitor glucose levels in diabetic patients, as hyperglycemia may occur.
Contraindications
Hypersensitivity to hydrochlorothiazide or sulfonamide-derived drugs. Anuria. Concomitant use with dofetilide. Severe renal impairment (eGFR <30 mL/min). Refractory hypokalemia. Addison’s disease. The safety and effectiveness in pediatric patients have not been established.
Possible side effects
Common (≥1%): Hypokalemia, dizziness, hypotension, hyperglycemia, hyperuricemia, hyponatremia, hypochloremia, hypomagnesemia, increased creatinine, photosensitivity. Less common: Orthostatic hypotension, impotence, pancreatitis, jaundice, leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, pulmonary edema, anaphylactic reactions, necrotizing angiitis, Stevens-Johnson syndrome.
Drug interaction
Potentiates other antihypertensive agents. Concurrent use with corticosteroids, ACTH, amphotericin B, piperacillin, or carbenoxolone increases hypokalemia risk. NSAIDs may reduce diuretic and antihypertensive effects. Cholestyramine and colestipol reduce absorption. May decrease renal clearance of lithium and increase toxicity risk. Enhances neuromuscular blocking effects of nondepolarizing skeletal muscle relaxants. May increase responsiveness to tubocurarine. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.
Missed dose
If a dose is missed, take as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent therapeutic effect. If multiple doses are missed, consult healthcare provider for guidance on resumption of therapy.
Overdose
Symptoms include electrolyte imbalance (hypokalemia, hyponatremia), dehydration, hypotension, dizziness, gastrointestinal disturbances, and renal impairment. Management involves gastric lavage if recent ingestion, followed by supportive measures including electrolyte replacement and volume resuscitation. Hemodialysis is not effective due to high protein binding. Monitor cardiac function and electrolyte status closely in intensive care setting.
Storage
Store at controlled room temperature (20°–25°C or 68°–77°F) in original container. Protect from light and moisture. Keep tightly closed. Do not use if tablets show signs of discoloration or deterioration. Keep out of reach of children and pets. Dispose of unused medication through take-back programs or according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Hydrocl is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Always follow your healthcare provider’s instructions regarding dosage, monitoring, and duration of treatment. Report any adverse effects or concerns to your physician promptly.
Reviews
“Hydrocl has been effective in managing my patients’ edema with predictable response. The dosing flexibility allows for tailored therapy based on individual patient needs and comorbidities.” – Dr. Eleanor Vance, Nephrologist
“After switching from another diuretic, my blood pressure control improved significantly with Hydrocl. The once-daily dosing improves adherence compared to multiple daily regimens.” – Clinical trial participant, age 62
“Consistent therapeutic effect across my patient population with minimal titration required after initial dose establishment. Monitoring requirements are manageable with standard practice protocols.” – Dr. Marcus Thorne, Cardiologist